SUMOylation of AnxA6 facilitates EGFR-PKCα complex formation to suppress epithelial cancer growth

Background The Annexin A6 (AnxA6) protein is known to inhibit the epidermal growth factor receptor (EGFR)-extracellular signal regulated kinase (ERK)1/2 signaling upon EGF stimulation.

While the biochemical mechanism of AnxA6 inactivating phosphorylation of EGFR and ERK1/2 is not completely explored in cancer cells.

Methods Cells were transiently co-transfected with pFlag-AnxA6, pHA-UBC9 and pHis-SUMO1 plasmids to enrich the SUMOylated AnxA6 by immunoprecipitation, and the modification level of AnxA6 by SUMO1 was detected by Western blot against SUMO1 antibody.

The SUMOylation level of AnxA6 was compared in response to chemical SUMOylation inhibitor treatment.

AnxA6 SUMOylation sites were further identified by LC–MS/MS and amino acid site mutation validation.

AnxA6 gene was silenced through AnxA6 targeting shRNA-containing pLKO.1 lentiviral transfection in HeLa cells, while AnxA6 gene was over-expressed within the Lenti-Vector carrying AnxA6 or mutant AnxA6^K299R plasmid in A431 cells using lentiviral infections.

Moreover, the mutant plasmid pGFP-EGFR^T790M/L858R was constructed to test AnxA6 regulation on EGFR mutation-induced signal transduction.

Moreover, cell proliferation, migration, and gefitinib chemotherapy sensitivity were evaluated in HeLa and A431 cells under AnxA6 konckdown or AnxA6 overexpression by CCK8, colony form and wound healing assays.

And tumorigenicity in vivo was measured in epithelial cancer cells-xenografted nude mouse model.

Results AnxA6 was obviously modified by SUMO1 conjugation within Lys (K) residues, and the K299 was one key SUMOylation site of AnxA6 in epithelial cancer cells.

Compared to the wild type AnxA6, AnxA6 knockdown and its SUMO site mutant AnxA6^K299R showed less suppression of dephosphorylation of EGFR-ERK1/2 under EGF stimulation.

The SUMOylated AnxA6 was prone to bind EGFR in response to EGF inducement, which facilitated EGFR-PKCα complex formation to decrease the EGF-induced phosphorylation of EGFR-ERK1/2 and cyclin D1 expression.

Similarly, AnxA6 SUMOylation inhibited dephosphorylation of the mutant EGFR, thereby impeding EGFR mutation-involved signal transduction.

Moreover, AnxA6 knockdown or the K299 mutant AnxA6^K299R conferred AnxA6 inability to suppress tumor progression, resulting in drug resistance to gefitinib in epithelial cancer cells.

And in epithelial cancer cells-xenografted nude mouse model, both the weight and size of tumors derived from AnxA6 knockdown or AnxA6^K299R mutation-expressing cells were much greater than that of AnxA6-expressing cells.

Conclusions Besides EGFR gene mutation, protein SUMOylation modification of EGFR-binding protein AnxA6 also functions pivotal roles in mediating epithelial cancer cell growth and gefitinib drug effect.

Video Abstract